Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

BACKGROUND: Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lusingu, John PA, Gesase, Samwel, Msham, Salum, Francis, Filbert, Lemnge, Martha, Seth, Misago, Sembuche, Samwel, Rutta, Acleus, Minja, Daniel, Segeja, Method D, Bosomprah, Samuel, Cousens, Simon, Noor, Ramadhani, Chilengi, Roma, Druilhe, Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720982/
https://ncbi.nlm.nih.gov/pubmed/19607731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-8-163
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados